Participant‐reported pain relief of 50% or greater · patients with pain in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported pain relief of 50% or greater · intensive care unit in India
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · intensive care unit in India
1 finding from 1 review
no estimate extracted
24 participants
Very low
Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · intensive care unit in India
1 finding from 1 review
no estimate extracted
24 participants
Very low
Rescue analgesic consumption · intensive care unit in India
It is very uncertain whether gabapentin changes rescue analgesic consumption compared with carbamazepine (very low certainty).
1 finding from 1 review
no estimate extracted
24 participants
Very low
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes pain score (numerical rating scale of 0 to 10: 0 = no pain, 10 =… compared with placebo (very low certainty).
1 finding from 1 review
Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes sedation score (numerical rating scale of 1 to 6: 0 = anxious,… compared with placebo (very low certainty).
1 finding from 1 review
Rescue analgesic consumption · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes rescue analgesic consumption compared with placebo (very low certainty).
1 finding from 1 review
Nausea · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes nausea compared with placebo (very low certainty).
1 finding from 1 review
Constipation · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes constipation compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: drowsiness (gabapentin alone) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin 300 mg/day) changes adverse effects: drowsiness (gabapentin alone) compared with placebo (very low certainty).
1 finding from 1 review
Hot flush frequency (number/day) · patients with hot flushes in women with a history of breast cancer
1 finding from 1 review
Hot flushes score Number of HF x severity (from 1 to 4) ( · patients with hot flushes in women with a history of breast cancer
1 finding from 1 review
Acquiring ability to walk · adults with SMA types II and III
1 finding from 1 review
Change in quality of life · adults with SMA types II and III
1 finding from 1 review
Change in pulmonary function · adults with SMA types II and III
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · adults with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · adults with SMA types II and III
1 finding from 1 review
Change in disability score · adults with SMA types II and III
1 finding from 1 review
Muscle strength · adults with SMA types II and III
1 finding from 1 review